Jefferies analyst Brandon Couillard reiterated a Hold rating on Genomic Health (NASDAQ: GHDX) today and set a price target of $50. The company’s shares closed yesterday at $54.45, close to its 52-week high of $59.43.
According to TipRanks.com, Couillard is a top 100 analyst with an average return of 28.2% and a 75.1% success rate. Couillard covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Organovo Holdings, and Exact Sciences.
The word on The Street in general, suggests a Hold analyst consensus rating for Genomic Health with a $51.10 average price target, which is a -6.2% downside from current levels. In a report issued on July 27, Piper Jaffray also maintained a Hold rating on the stock with a $50 price target.
.
See today’s analyst top recommended stocks >>
Based on Genomic Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $3.78 million. In comparison, last year the company had a GAAP net loss of $2.74 million.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GHDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genomic Health, Inc. provides genomic-based diagnostic tests, which analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. It uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning.
